公开(公告)号：US20170137469A1

公开(公告)日：2017-05-18

申请号：US15301310

申请日：2015-04-01

Applicant: MONASH UNIVERSITY

Inventor： Jian LI ,  Roger NATION ,  Tony VELKOV ,  Philip THOMPSON ,  Kade D. ROBERTS

IPC: C07K7/62 ,  A61K38/12

CPC classification number: C07K7/62 ,  A61K38/00 ,  A61K38/12

Abstract: The present invention relates to antimicrobial compounds and their uses, and in particular to peptide antibiotics which may be used in the treatment of bacterial infections such as Gram-negative bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens.

公开(公告)号：US20180170891A1

公开(公告)日：2018-06-21

申请号：US15572554

申请日：2016-05-06

Applicant: Monash University ,  The Florey Institute of Neuroscience and Mental Health ,  St. Vincent's Institute of Medical Research

Inventor： Siew Yeen CHAI ,  Philip THOMPSON ,  Simon MOUNTFORD ,  Michael W. PARKER

IPC: C07D309/32 ,  A61P25/28 ,  C07D405/10 ,  C07D405/04 ,  C07D409/10

CPC classification number: C07D309/32 ,  A61P25/28 ,  C07D405/04 ,  C07D405/10 ,  C07D407/10 ,  C07D409/10 ,  C07D493/04

Abstract: The present disclosure relates generally, but not exclusively, to compounds and their use in therapy, to compositions and agents comprising said compounds, to methods of treatment using said compounds, and their use in the manufacture of medicaments. The disclosure further relates to inhibitors of IRAP and their use in the treatment or prevention of Alzheimer's disease and the treatment and prevention of memory and cognitive disorders.

公开(公告)号：US20230312577A1

公开(公告)日：2023-10-05

申请号：US18000632

申请日：2021-06-04

Applicant: MONASH UNIVERSITY ,  PETER MACCALLUM CANCER INSTITUTE

Inventor： Philip THOMPSON ,  Jake SHORTT ,  Ricky JOHNSTONE ,  Xiao MA ,  Danielle OH ,  Ian JENNINGS

IPC: C07D487/04 ,  C07D495/04 ,  C07D471/04 ,  A61P35/00

CPC classification number: C07D487/04 ,  C07D495/04 ,  C07D471/04 ,  A61P35/00

Abstract: Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.